BioDlink International Company Limited (HKG:1875)

Hong Kong · Delayed Price · Currency is HKD

4.110

-0.120 (-2.84%)

May 28, 2026, 11:59 AM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Anti-Tumor Drugs, CDMO/CMO and License-Out of Self-Developed Biological Drugs			780.63M	442.18M	76.33M	22.49M	45.31M
Anti-Tumor Drugs, CDMO/CMO and License-Out of Self-Developed Biological Drugs Growth			76.54%	479.34%	239.36%	-50.36%	15.53%
Total			780.63M	442.18M	76.33M	22.49M	45.31M
Total Growth			76.54%	479.34%	239.36%	-50.36%	15.53%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Mainland China			780.63M	442.18M	76.33M	22.49M	45.31M
Mainland China Growth			76.54%	479.34%	239.36%	-50.36%	15.53%
Total			780.63M	442.18M	76.33M	22.49M	45.31M
Total Growth			76.54%	479.34%	239.36%	-50.36%	15.53%

Source: S&P Global Market Intelligence.